Brief: RenovoRx Q2 Net Income USD -2.895 Million
14/08/2025 21:05
Aug 14 (Reuters) - RenovoRx Q2 basic EPS USD -0.08. Q2 operating expenses USD 2.948 million
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies